:Edivoxetine
{{Short description|Chemical compound}}
{{Drugbox
| IUPAC_name = (1R)-2-(5-fluoro-2-methoxyphenyl)-1-[(2S)-morpholin-2-yl]-1-(tetrahydro-2H-pyran-4-yl)ethanol
| image = Edivoxetine.svg
| width = 180
| image2 = Edivoxetine ball-and-stick model.png
| CAS_number = 1194508-25-2
| CAS_supplemental =
1194374-05-4 (hydrochloride)
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 3W9N3F4JOO
| ATC_prefix = None
| ATC_suffix =
| PubChem = 11186829
| KEGG = D09890
| C = 18 | H = 26 | F = 1 | N = 1 | O = 4
| ChemSpiderID = 9361913
| smiles = COC1=C(C=C(C=C1)F)C[C@]([C@@H]2CNCCO2)(C3CCOCC3)O
| StdInChI = 1S/C18H26FNO4/c1-22-16-3-2-15(19)10-13(16)11-18(21,14-4-7-23-8-5-14)17-12-20-6-9-24-17/h2-3,10,14,17,20-21H,4-9,11-12H2,1H3/t17-,18+/m0/s1
| StdInChIKey = CPBHSHYQQLFAPW-ZWKOTPCHSA-N
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| pregnancy_category =
| legal_status = Development terminated
| routes_of_administration =
}}
Edivoxetine (INN; code name LY-2216684) is a drug which acts as a selective norepinephrine reuptake inhibitor and was under development by Eli Lilly for attention-deficit disorder (ADD) and as an antidepressant treatment.{{cite journal | author = Jun Yan | title = Pipeline for new antidepressants flowing slowly |newspaper= Psychiatric News | volume = 47 | issue = 5 | page = 1b–29 |date=March 2012 |via= American Psychiatric Association | doi = 10.1176/pn.47.5.psychnews_47_5_1-b| url = http://dsm.psychiatryonline.org/newsarticle.aspx?articleid=1032188 | access-date = 2012-04-27| url-access = subscription }}{{cite press release | title = Statement on a nonproprietary name adopted by the USAN council - Edivoxetine | publisher = American Medical Association | year = 2012 | url = http://www.ama-assn.org/resources/doc/usan/edivoxetine.pdf | access-date = 2012-04-12}} It was in phase III clinical trials in 2012 for major depressive disorder, but failed to get approval.{{cite journal | author = Chancellor D | title = The depression market | journal = Nature Reviews. Drug Discovery | volume = 10 | issue = 11 | pages = 809–10 |date=November 2011 | pmid = 22037032 | doi = 10.1038/nrd3585 | s2cid = 3194093 }}
Effectiveness
In a study published in 2010, edivoxetine succeeded to prove superiority over placebo, as measured by Hamilton Depression Rating Scale. However, effectiveness could be observed using the Self-Rated Quick Inventory of Depressive Symptomatology.{{cite journal |vauthors=Dubé S, Dellva MA, Jones M, Kielbasa W, Padich R, Saha A, Rao P | title = A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression | journal = Journal of Psychiatric Research | volume = 44 | issue = 6 | pages = 356–363 |date=April 2010 | pmid = 19909980 | doi = 10.1016/j.jpsychires.2009.09.013}}
In a study published in 2011, using the Montgomery–Åsberg Depression Rating Scale and the Sheehan Disability Scale, edivoxetine showed superiority over placebo, with higher response and remission rates.{{cite journal |vauthors=Pangallo P, Dellva MA, D'Souza DN, Essink B, Russell J, Goldberger C | title = A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder | journal = Journal of Psychiatric Research | volume = 45 | issue = 6 | pages = 748–755 |date=June 2011 | pmid = 21511276 | doi = 10.1016/j.jpsychires.2011.03.014}}
In December 2013, Eli Lilly announced that the clinical development of edivoxetine will be stopped due to lack of efficacy compared to SSRI alone in three separate clinical trials.{{Cite web|url=https://investor.lilly.com/releasedetail.cfm?ReleaseID=811751|title = Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder | Eli Lilly and Company}}
Side effects
Side effects significantly associated with edivoxetine are headache, nausea, constipation, dry mouth and insomnia.
The above-mentioned studies report increases of the cardiac rhythm, and one also increases of diastolic and systolic blood pressures.
See also
References
{{Reflist}}
{{ADHD pharmacotherapies}}
{{Antidepressants}}
{{Monoamine reuptake inhibitors}}
Category:Drugs developed by Eli Lilly and Company